PET–Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors

Research output: Contribution to journalReview article

Abstract

18F-FDG PET/CT has been described as an accurate tool for initial diagnosis of pancreatic adenocarcinoma. It differentiates benign from malignant causes; detects local and, especially, distant spread of disease; and is a very good predictor of patient prognosis. Pancreatic neuroendocrine tumors are rare tumors that originate from the islet cells of the pancreas. Currently, 68Ga-DOTA-labeled somatostatin analogs are considered the best modality for detection of well-differentiated neuroendocrine tumors. 18F-FDG PET/CT has a role in patients with poorly differentiated tumors. Recent studies have demonstrated improved survival in patients with metastatic neuroendocrine tumors treated with radiolabeled somatostatin analogs.

Original languageEnglish (US)
Pages (from-to)407-421
Number of pages15
JournalPET Clinics
Volume12
Issue number4
DOIs
StatePublished - Oct 1 2017

Fingerprint

Precision Medicine
Neuroendocrine Tumors
medicine
Adenocarcinoma
tumors
tomography
Tomography
Fluorodeoxyglucose F18
Somatostatin
Islet Cell Adenoma
Pancreas
analogs
pancreas
prognosis
Survival
Neoplasms
causes
predictions
cells

Keywords

  • Pancreatic adenocarcinoma
  • Pancreatic cancer
  • Pancreatic neuroendocrine tumor
  • PET
  • PET/CT

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging

Cite this

@article{b22fb37ccfc549fcaf2f2542b0f81eee,
title = "PET–Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors",
abstract = "18F-FDG PET/CT has been described as an accurate tool for initial diagnosis of pancreatic adenocarcinoma. It differentiates benign from malignant causes; detects local and, especially, distant spread of disease; and is a very good predictor of patient prognosis. Pancreatic neuroendocrine tumors are rare tumors that originate from the islet cells of the pancreas. Currently, 68Ga-DOTA-labeled somatostatin analogs are considered the best modality for detection of well-differentiated neuroendocrine tumors. 18F-FDG PET/CT has a role in patients with poorly differentiated tumors. Recent studies have demonstrated improved survival in patients with metastatic neuroendocrine tumors treated with radiolabeled somatostatin analogs.",
keywords = "Pancreatic adenocarcinoma, Pancreatic cancer, Pancreatic neuroendocrine tumor, PET, PET/CT",
author = "Pinho, {Daniella F.} and Subramaniam, {Rathan M.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.cpet.2017.05.003",
language = "English (US)",
volume = "12",
pages = "407--421",
journal = "PET Clinics",
issn = "1556-8598",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - PET–Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors

AU - Pinho, Daniella F.

AU - Subramaniam, Rathan M.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - 18F-FDG PET/CT has been described as an accurate tool for initial diagnosis of pancreatic adenocarcinoma. It differentiates benign from malignant causes; detects local and, especially, distant spread of disease; and is a very good predictor of patient prognosis. Pancreatic neuroendocrine tumors are rare tumors that originate from the islet cells of the pancreas. Currently, 68Ga-DOTA-labeled somatostatin analogs are considered the best modality for detection of well-differentiated neuroendocrine tumors. 18F-FDG PET/CT has a role in patients with poorly differentiated tumors. Recent studies have demonstrated improved survival in patients with metastatic neuroendocrine tumors treated with radiolabeled somatostatin analogs.

AB - 18F-FDG PET/CT has been described as an accurate tool for initial diagnosis of pancreatic adenocarcinoma. It differentiates benign from malignant causes; detects local and, especially, distant spread of disease; and is a very good predictor of patient prognosis. Pancreatic neuroendocrine tumors are rare tumors that originate from the islet cells of the pancreas. Currently, 68Ga-DOTA-labeled somatostatin analogs are considered the best modality for detection of well-differentiated neuroendocrine tumors. 18F-FDG PET/CT has a role in patients with poorly differentiated tumors. Recent studies have demonstrated improved survival in patients with metastatic neuroendocrine tumors treated with radiolabeled somatostatin analogs.

KW - Pancreatic adenocarcinoma

KW - Pancreatic cancer

KW - Pancreatic neuroendocrine tumor

KW - PET

KW - PET/CT

UR - http://www.scopus.com/inward/record.url?scp=85023625779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023625779&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2017.05.003

DO - 10.1016/j.cpet.2017.05.003

M3 - Review article

C2 - 28867112

AN - SCOPUS:85023625779

VL - 12

SP - 407

EP - 421

JO - PET Clinics

JF - PET Clinics

SN - 1556-8598

IS - 4

ER -